Gillian M. Cannon

Gillian M. Cannon, PhD, became a member of our Board in November 2020. Dr. Cannon is currently President of Alyvant and Executive in Residence for Roivant Sciences. Dr. Cannon brings to Corcept more than 30 years of experience in the pharmaceutical industry, where she has served in leadership roles at Merck and Co. Inc., UCB Inc. and Otsuka Pharmaceuticals. In her 27-year career at Merck, Dr. Cannon held a variety of senior positions, including Global Vice President for Commercial Operations at Merck’s start-up biosimilar business, Merck BioVentures; Business Unit Head for Merck’s specialty products franchise; and Global Commercial Head of its neuroscience franchise. Dr. Cannon currently serves as a Board Director for Affibody AB, a Swedish biotechnology company. She holds a Bachelor of Science in biochemistry from the University of Edinburgh, Scotland and a PhD in health administration from the Temple University School of Business.